GleamWall
中文EN

NIKI Niki BioSolutions, Inc.

Measuring & Controlling Devices, NEC · Nasdaq · SEC CIK 1734005 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-66.7%
TTM net income YoY71.2%
TTM EPS YoY77.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin2.4%
Operating margin—
Net margin-654.8%
FCF margin-1,791.3%
EBITDA margin—

Returns

ROE-13.9%
ROA-13.6%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.73x
Accruals ratio23.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q3*2025-09-302024Q4*2024-12-312024Q3*2024-09-30
Income statement
Revenue————
R&D expense$91,711$241,793-$284,466$440,704
SG&A expense$211,717$173,920$98,823$244,476
Net income-$307,495-$613,995-$919,900-$704,110
EPS (diluted)————
Balance sheet
Cash & equivalents$3.45M$2.27M$874,238$754,592
Current assets$3.59M$2.48M$959,554—
Total assets$18.69M$17.58M$16.13M—
Current liabilities$4.59M$4.42M$4.34M—
Total liabilities$4.90M$4.42M$4.35M—
Shareholders' equity$23.12M$22.53M$21.13M$12.51M
Cash flow statement
Operating cash flow-$535,719-$484,283$119,646-$28,493
Investing cash flow——$0$0
Financing cash flow$1.72M$0——
Depreciation & amortization——$19,219-$19,219

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.